002872 ST天圣制药
2026/09 - 九个月2025/122024/122023/122022/12

盈利能力分析
净资产收益率 ROE (%)-2.268-2.801-4.267-4.355-4.065
总资产报酬率 ROA (%)-1.681-2.060-3.151-3.220-2.974
投入资产回报率 ROIC (%)-1.879-2.317-3.574-3.701-3.376

边际利润分析
销售毛利率 (%)46.18049.11647.65247.08356.574
营业利润率 (%)-13.414-12.271-16.505-16.152-13.955
息税前利润/营业总收入 (%)-11.810-11.228-16.092-15.196-12.495
净利润/营业总收入 (%)-13.054-10.895-15.472-16.176-15.083

收益指标分析
经营活动净收益/利润总额(%)147.175105.86273.922101.621125.389
价值变动净收益/利润总额(%)-4.824-10.106-16.938-2.123-5.850
营业外收支净额/利润总额(%)0.186-2.0273.8431.214-0.701

偿债能力分析
流动比率 (X)1.2871.6351.9551.5201.469
速动比率 (X)1.1021.3911.6581.2211.234
资产负债率 (%)25.29825.92126.38025.44526.360
带息债务/全部投入资本 (%)11.40011.57610.4736.8267.155
股东权益/带息债务 (%)727.193715.236788.7911,244.1261,188.356
股东权益/负债合计 (%)294.246284.670277.872292.414278.749
利息保障倍数 (X)-7.249-14.064-15.000-13.169-9.164

营运能力分析
应收账款周转天数 (天)85.30981.60384.23590.60092.643
存货周转天数 (天)143.040143.204146.673156.822174.443